Results 151 to 160 of about 10,359,574 (255)

Generative models for antimicrobial peptide design: auto-encoders and beyond. [PDF]

BioData Min
Beierle L, Hahnfeld J, Goesmann A, Mostolizadeh R, Cemič F.   +4 more
europepmc   +1 more source

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors. [PDF]

J Chem Inf Model, 2023
Vishnoi S, Bhattacharya S, Walsh EM, Okoh GI, Thompson D.   +4 more
europepmc   +1 more source

Safety and Efficacy of GLP‐1 Receptor Agonists in Adults With Epilepsy, Obesity, and Type 2 Diabetes

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Managing obesity in patients with epilepsy is complicated by the weight‐gaining properties of essential antiseizure medications (ASMs) such as valproate and pregabalin. We evaluated the safety and efficacy of initiating glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in this population.
Hyoshin Son, Inyoung Hwang, Sang Won Lee, Yun Kim   +3 more
wiley   +1 more source

Isolation and genomic analysis of otomycosis pathogens, and genomics-informed antimicrobial peptide design with potential therapeutic applications. [PDF]

BMC Microbiol
Shi W, Hu J, Jiang Q, Xu Y, Li R, Xu H, Zhang G, Cui Z, Ouyang R, Wu W, Li Y, Hong H, Mou X, Zhao W, Chou S.   +14 more
europepmc   +1 more source

Early Clinical and Cerebrospinal Fluid Predictors of 1‐Year Recurrence in Autoimmune GFAP Astrocytopathy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP‐A) is an inflammatory central nervous system disorder with variable outcomes. Relapse occurs in a subset of patients, but early predictors remain unclear. We aimed to identify admission‐available features associated with 1‐year recurrence and develop an interpretable ...
Qingting Hong, Yuping Xiao, Yuhan Wu, Ziyuan Huang, Weishan Liang, Li Xiao, Yaqing Shu, Tingting Lu, Yanyu Chang, Wei Qiu, Yuge Wang   +10 more
wiley   +1 more source

MAP Crosslinker Chirality Regulates Macrophage Polarization Through MD-2 Engagement and Enables Tunable Immunomodulation Through Novel Peptide Design. [PDF]

Adv Healthc Mater
Suarez-Arnedo A, Thomas JL, Liu Y, Cordero-Alvarado P, Kim A, Espinoza AC, Harvey L, Poysungnoen K, Lin F, Ye Z, Segura T.   +10 more
europepmc   +1 more source

Cell-permeable chameleonic peptides: Exploiting conformational dynamics in de novo cyclic peptide design. [PDF]

Curr Opin Struct Biol, 2023
Ramelot TA, Palmer J, Montelione GT, Bhardwaj G.   +3 more
europepmc   +1 more source

Associations of Rheumatoid Arthritis Disease Activity With Frailty Over Five Years of Follow‐up

Arthritis Care &Research, EarlyView.
Objective To evaluate whether rheumatoid arthritis (RA) disease activity is associated with frailty both in cross‐section and longitudinally. Methods Participants within the Veterans Affairs Rheumatoid Arthritis (VARA) registry enrolled from 2003 to 2022 were included.
Courtney N. Loecker, Yangyuna Yang, Punyasha Roul, Aaron Baraff, Myra S. Schmaderer, Lani Zimmerman, Kaleb Michaud, Namrata Singh, Grant W. Cannon, Gary Kunkel, Ted R. Mikuls, Ariela R. Orkaby, Joshua F. Baker, Bryant R. England, Katherine D. Wysham   +14 more
wiley   +1 more source

Author Correction: De novo antioxidant peptide design via machine learning and DFT studies. [PDF]

Sci Rep
Hesamzadeh P, Seif A, Mahmoudzadeh K, Ganjali Koli M, Mostafazadeh A, Nayeri K, Mirjafary Z, Saeidian H.   +7 more
europepmc   +1 more source

Artificial Intelligence in Systemic Sclerosis: Clinical Applications, Challenges, and Future Directions

Arthritis Care &Research, EarlyView.
Systemic sclerosis (SSc) is a rare autoimmune disease defined by immune dysregulation, vasculopathy, and progressive fibrosis of the skin and internal organs. Despite advances in care, major complications such as interstitial lung disease (ILD) and myocardial involvement remain the leading causes of morbidity and mortality.
Cristiana Sieiro Santos, José Miguel Sequí‐Sabater, Diego Benavent   +2 more
wiley   +1 more source